

|  |  |   |
|--|--|---|
| <b>Statement of Deficiencies</b>   | <b>(X1) Provider/Supplier/CLIA Identification Number</b><br><br>13D0522334 | <b>(X3) Date Survey Completed</b><br><br>05/12/2021 |
| <b>Name of Provider or Supplier</b><br><br>Benewah Community Hospital  | <b>Street Address, City, State</b><br><br>229 S 7th St, Saint Maries, ID   |   |
| For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency. |  |   |

| <b>(X4) ID Prefix Tag</b> | <b>Summary Statement of Deficiencies</b>  |
|---------------------------|---|
| <b>D5447</b>              | <p><b>CONTROL PROCEDURES</b><br/>CFR(s): 493.1256(d)(3)(i)(g)</p> <p>Unless CMS Approves a procedure, specified in Appendix C of the State Operations Manual (CMS Pub. 7), that provides equivalent quality testing, the laboratory must-- At least once a day patient specimens are assayed or examined perform the following for-- Each quantitative procedure, include two control materials of different concentrations; (g) The laboratory must document all control procedures performed.</p> <p>This STANDARD is not met as evidenced by:<br/>Based on a random record review of Quality Control (QC) documentation and an interview with the laboratory manager on 5/12/2021, the laboratory failed to successfully perform two levels of QC daily for each quantitative procedure. The findings include: 1. A random record review of QC from the Siemens Dimension EXL identified that the laboratory did not have an acceptable result for level 1 total bilirubin QC on 6/6/2020. The laboratory performed and released six (6) patient total bilirubin tests on 6/6/2020. 2. An interview with the laboratory manager on 5/12/2021 at 3:28 pm confirmed that the laboratory failed to have two acceptable QC levels for total bilirubin on 6/6/2020.</p> |
| <b>D6086</b>              | <p><b>LABORATORY DIRECTOR RESPONSIBILITIES</b><br/>CFR(s): 493.1445(e)(3)(ii)</p> <p>The laboratory director must ensure that verification procedures used are adequate to determine the accuracy, precision, and other pertinent performance characteristics of the method.</p> <p>This STANDARD is not met as evidenced by:<br/>Based on record review of instrument verifications and an interview with the</p>  |

laboratory manager on 05/12/2021, the Laboratory Director (LD) failed to ensure that verification procedures that were used for verification of the Sysmex CA-640 were adequate to determine the accuracy, precision, and other pertinent performance characteristics of the method before their use in patient testing. The findings include:

1. A record review of the Sysmex CA-640 verification performed in June 2019, identified that the Laboratory Director failed to approve verification of performance of prothrombin time, partial thromboplastin time and D-dimer testing before implementation of patient testing.
2. An interview with the laboratory manager on 5/12/2021 at 11:20 am confirmed that the Laboratory Director failed to approve and sign the performance verification of the Sysmex CA-640 before patient testing was implemented.